ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Apr 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
May 2026
Nuclear Technology
February 2026
Fusion Science and Technology
Latest News
DTRA’s advancements in nuclear and radiological detection
A new, more complex nuclear age has begun. Echoing the tensions of the Cold War amid rapidly evolving nuclear and radiological threats, preparedness in the modern age is a contest of scientific innovation. The Research and Development Directorate (RD) at the Defense Threat Reduction Agency (DTRA) is charged with winning this contest.
Greg Staack, Yung-Sung Cheng, Yue Zhou, Tom LaBone
Fusion Science and Technology | Volume 71 | Number 4 | May 2017 | Pages 570-574
Technical Note | doi.org/10.1080/15361055.2017.1291041
Articles are hosted by Taylor and Francis Online.
Samples of tritiated LaNi4.15Al0.85 (LANA.85) and 13X zeolite were analyzed to obtain particle size distributions and tritium evolution rates in a simulated lung environment. This information was used to calculate intake-to-dose conversion factors (DCFs), which estimate the committed effective dose (CED) a worker would receive after inhaling either tritiated particulate. The DCFs for tritiated LANA.85 and 13X particulate with a default activity mean aerodynamic diameter (AMAD) of 5 μm were determined to be 1.01E-11 Sv/Bq and 1.11E-11 Sv/Bq, respectively. These results are comparable to that of HTO, 1.8E-11 Sv/Bq, indicating that urine bioassay results can conservatively estimate the dose delivered if the worker was exposed to any mixture of HTO, LANA.85, or 13X.
